CARMEL, Calif.--(BUSINESS WIRE)--Carmel-based PathogenX Inc., which develops, manufactures and distributes proprietary technology designed to dramatically simplify the process of medical waste disposal, today announced it is approved for full national sales throughout Canada for its unique, double-batch, on-site sterilization device, the PX2.
PathogenX’s PX2 is a stand-alone device (about the size of a laser printer) that safely and efficiently renders regulated medical waste (such as sharps and red-bag waste) completely sterile, unrecognizable and non-reusable in compliance with all federal EPA, CDC and OSHA standards and guidelines. Each PX2 device is capable of processing up to 12 gallons of medical waste per day.
The PX2 system destroys all microbes, including COVID-19, while melting the biomedical waste so that a resulting “brick” of harmless, sterilized material can be easily disposed of in the standard trash.
The PX2 technology is available throughout the United States and now Canada for use by hospitals and health facilities; research centers and laboratories; mortuary and autopsy centers; animal research and testing laboratories; veterinary facilities; blood banks; nursing homes for the elderly; and other health-related venues where blood is drawn.
“Full Canadian approval and distribution of PX2 is a landmark growth moment for PathogenX,” said Chuck Berkeley, PathogenX’s CEO and Board Chairman. “It’s a natural next step, too, as our technology is actually manufactured in Toronto, Canada by Mara Technologies. PX2 is a genuine game-changer for physicians, veterinarian practices, sports teams, schools, nursing homes, and any other organizations throughout Canada that have been dealing with the expensive and dangerous nuisance of generating modest amounts of medical waste. With the ongoing battle against COVID-19, we are also proud to provide a safety net to healthcare workers on the front lines – now in both the US and Canada – that removes the risk-related issues of having to manage contaminated sharps.”
Berkeley added that PathogenX is also currently in the approval processes for several additional major international markets and will have a substantial global presence by the end of 2021.
Disposing of medical waste on-site with the PX2 is considerably less expensive than haul-and-treat services and the company offers its customers financing options to meet their practice needs- purchase, rent, or lease-to-own.
The mission of PathogenX, Inc. is to reimagine and change the way nearly one million U.S. low-volume generators manage their infectious waste by offering an economic, efficient and environmentally safe solution, which also serves to eliminate liability. Learn more at pathogenx.com.
Note to media: photos of PX2 device and images of post-PX2’d medical waste – rendered harmless and fully sterilized, are available upon request.